VIR vs. IMVT, SRRK, CRSP, DNLI, TWST, VCEL, SWTX, KYMR, IOVA, and BEAM
Should you be buying Vir Biotechnology stock or one of its competitors? The main competitors of Vir Biotechnology include Immunovant (IMVT), Scholar Rock (SRRK), CRISPR Therapeutics (CRSP), Denali Therapeutics (DNLI), Twist Bioscience (TWST), Vericel (VCEL), SpringWorks Therapeutics (SWTX), Kymera Therapeutics (KYMR), Iovance Biotherapeutics (IOVA), and Beam Therapeutics (BEAM). These companies are all part of the "biological products, except diagnostic" industry.
Vir Biotechnology vs.
Immunovant (NASDAQ:IMVT) and Vir Biotechnology (NASDAQ:VIR) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, community ranking, analyst recommendations, media sentiment, dividends and institutional ownership.
Immunovant has higher earnings, but lower revenue than Vir Biotechnology. Immunovant is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
In the previous week, Immunovant had 5 more articles in the media than Vir Biotechnology. MarketBeat recorded 9 mentions for Immunovant and 4 mentions for Vir Biotechnology. Vir Biotechnology's average media sentiment score of 0.49 beat Immunovant's score of 0.31 indicating that Vir Biotechnology is being referred to more favorably in the news media.
47.1% of Immunovant shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 5.9% of Immunovant shares are held by company insiders. Comparatively, 15.6% of Vir Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Immunovant presently has a consensus price target of $47.22, suggesting a potential upside of 82.61%. Vir Biotechnology has a consensus price target of $36.40, suggesting a potential upside of 395.91%. Given Vir Biotechnology's higher possible upside, analysts clearly believe Vir Biotechnology is more favorable than Immunovant.
Immunovant received 74 more outperform votes than Vir Biotechnology when rated by MarketBeat users. Likewise, 78.34% of users gave Immunovant an outperform vote while only 53.26% of users gave Vir Biotechnology an outperform vote.
Immunovant has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, Vir Biotechnology has a beta of 0.49, meaning that its stock price is 51% less volatile than the S&P 500.
Immunovant has a net margin of 0.00% compared to Vir Biotechnology's net margin of -678.40%. Vir Biotechnology's return on equity of -36.71% beat Immunovant's return on equity.
Summary
Immunovant beats Vir Biotechnology on 9 of the 17 factors compared between the two stocks.
Get Vir Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vir Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:VIR) was last updated on 12/21/2024 by MarketBeat.com Staff
Free VIR Stock Alerts